Ceftizoxime Property

Melting point:

227° (dec)

Density 

1.89±0.1 g/cm3(Predicted)

storage temp. 

under inert gas (nitrogen or Argon) at 2–8 °C

solubility 

Aqueous Base (Slightly), DMSO (Slightly, Heated), Methanol (Slightly, Heated, Sonicated)

form 

Solid

pka

pKa 2.1 (Uncertain)

color 

White to Pale Yellow

Merck 

14,1951

Stability:

Hygroscopic

InChI

InChI=1S/C13H13N5O5S2/c1-23-17-7(5-4-25-13(14)15-5)9(19)16-8-10(20)18-6(12(21)22)2-3-24-11(8)18/h2,4,8,11H,3H2,1H3,(H2,14,15)(H,16,19)(H,21,22)/b17-7-/t8-,11-/m1/s1

InChIKey

NNULBSISHYWZJU-LLKWHZGFSA-N

SMILES

N12[C@@]([H])([C@H](NC(/C(/C3=CSC(N)=N3)=N\OC)=O)C1=O)SCC=C2C(O)=O

CAS DataBase Reference

68401-81-0(CAS DataBase Reference)

Safety

RTECS 

XI0367375

HS Code 

2941906000

Toxicity

LD50 intravenous in rat: 8gm/kg

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H315Causes skin irritation

H319Causes serious eye irritation

Precautionary statements

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P302+P352IF ON SKIN: wash with plenty of soap and water.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

P332+P313IF SKIN irritation occurs: Get medical advice/attention.

P337+P313IF eye irritation persists: Get medical advice/attention.

Ceftizoxime Chemical Properties,Usage,Production

Description

In ceftizoxime, the whole C-3 side chain has been omitted to prevent deactivation by hydrolysis. It rather resembles cefotaxime in its properties; however, not being subject to metabolism, its pharmacokinetic properties are much less complex.

Originator

Eposelin,Fujisawa,Japan,1982

Uses

Ceftizoxime is used for bacterial infections of the lower respiratory tract, infections of the urinary tract, infections of the bones, joints, skin, soft tissues, and abdominal infections. Synonyms of this drug are ceftix and eposerin.

Uses

Ceftizoxime is a cephalosporin based, potent antibacterial agent.

Uses

Antibacterial.

Definition

ChEBI: A parenteral third-generation cephalosporin, bearing a 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino group at the 7beta-position.

Manufacturing Process

Phosphorus oxychloride (2.0 g) was added at one time at 5°C to 10°C to a suspension of 2-methoxyimino-2-(2-amino-1,3-thiazol-4-yl)acetic acid (syn isomer) (2 g) in dry ethyl acetate (20 ml). After stirring for 20 minutes at 7°C to 10°C, bis(trimethylsilyl)acetamide (0.4 g) was added thereto at the same temperature. After stirring for 10 minutes at 7°C to 10°C, phosphorus oxychloride (2.0 g) was dropwise added thereto at the same temperature. The resulting mixture was stirred for 10 minutes at 7°C to 10°C, and dry dimethylformamide (0.8 g) was dropwise added thereto at the same temperature. The mixture was stirred for 30 minutes at 7°C to 10°C to give a clear solution. On the other hand, trimethylsilylacetamide (7.35 g) was added to a suspension of 7-aminocephalosporanic acid (2.45 g) in dry ethyl acetate (8 ml), after which the mixture was stirred at 40°C to give a clear solution.
To this solution was added at one time the above-obtained ethyl acetate solution at -15°C, and the resulting mixture was stirred for 1 hour at -10°C to -15°C. The reaction mixture was cooled to -30°C, and water (80 ml) was added thereto. The aqueous layer was separated, adjusted to pH 4.5 with sodium bicarbonate and subjected to column chromatography on Diaion HP-20 resin (Mitsubishi Chemical Industries Ltd.) using 25% aqueous solution of isopropyl alcohol as an eluent. The eluate was lyophilized to give 7-[2- methoxyimino-2-(2-amino-1,3-thiazol-4-yl)acetamido]cephalosporanic acid (syn isomer) (1.8 g), MP 227°C (decomp.).

brand name

Cefizox (Astellas).

Therapeutic Function

Antibacterial

Antimicrobial activity

A semisynthetic cephalosporin supplied as the sodium salt. The properties are very similar to those of cefotaxime, but it lacks the acetoxymethyl group at position C-4 and is therefore not subject to deacetylation. Activity against common pathogenic bacteria (Table 13.4) is very similar to that of cefotaxime.
A 500 mg intramuscular injection achieves a plasma concentration of around 14 mg/L. A concentration of 85–90 mg/L is produced 30 min at the end of a 30-min intravenous infusion. The plasma half-life is 1.3–1.9 h. Protein binding is 30%. It is well distributed. In children with meningitis receiving 200–250 mg/kg per day in four equally divided doses for 14–21 days, mean CSF concentrations 2 h after a dose were 6.4 mg/L on day 2 and 3.6 mg/L on day 14.
About 70–90% of the dose is recovered in the urine in the first 24 h, principally by glomerular filtration. Probenecid increases the plasma half-life by about 50%. In patients receiving 1 g intravenously over 30 min, the plasma elimination half-life rose to 35 h when the corrected creatinine clearance was <10 mL/ min. It is partly removed by peritoneal and hemodialysis.
Adverse reactions and clinical use are similar to those of cefotaxime.

Synthesis

Ceftizoxime, |á-O-methyloxime of (6R,7R)-7-[2-(2-amino-4-thiazolyl)glyoxylamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-2-carboxylic acid (32.1.2.64), is synthesized by the scheme described below, which begins with 4-nitrobenzyl ester of 3-hydroxy-7-(2-phenylacetamido)-3-cefem-4-carboxylic acid (32.1.2.57), which is synthesized using a number of methods used to synthesize cefaclor (32.1.2.48). Reducing the C3¨CC4 double bond in the initial 4-nitrobenzyl ester of 3-hydroxy-7-(2-phenylacetamido)-3-cefem- 4-carboxylic acid (32.1.2.57) with sodium borohydride in methanol, 4-nitrobenzyl ester of 3-hydroxy-7-(2-phenylacetamido)-3-cefam-4-carboxylic acid (32.1.2.58) is obtained, the hydroxyl group in which it is acylated by acetic anhydride in pyridine, forming acetate (32.1.2.59). Reacting this with triethylamine removes a molecule of acetic acid, giving the 4-nitrobenzyl ester of 7-(2-phenylacetamido)-3-cefem-4-carboxylic acid (32.1.2.60). Reacting this with phosphorous pentachloride in pyridine, followed by subsequent methanolysis deacylates the amide fragment of the molecule, giving the 4-nitrobenzyl ester of 7-amino- 3-cefem-4-carboxylic acid (32.1.2.61).
Preliminary silylation of the amino group of this compound with trimethylsilylacetamide and subsequent acylation with 2-(2-formamido-4-thiazolyl)-2-methoxyminoacetic acid chloride synthesized directly in reaction conditions by reacting with phosphorous chloroxide in dimethylformamide gives the 4-nitro-benzyl ester of |á-O-methyloxime of 7-[2-(2-formamido-4-thiazolyl)glyoxylamido]-8-oxo-t-thia-1-azabicyclo[4.2.0]oct-2-en-2-carboxylic acid (32.1.2.62). Reducing this with hydrogen using a palladium on carbon catalyst removes the 4-nitrobenzyl protection from the carboxyl group, forming the acid (32.1.2.63). Finally, hydrolysis of the formamide region of the molecule using hydrogen chloride in methanol gives the desired ceftizoxime (32.1.2.64).